Brian W. Ogilvie

1.3k total citations
24 papers, 955 citations indexed

About

Brian W. Ogilvie is a scholar working on Oncology, Pharmacology and Molecular Biology. According to data from OpenAlex, Brian W. Ogilvie has authored 24 papers receiving a total of 955 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 13 papers in Pharmacology and 4 papers in Molecular Biology. Recurrent topics in Brian W. Ogilvie's work include Pharmacogenetics and Drug Metabolism (12 papers), Drug Transport and Resistance Mechanisms (10 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Brian W. Ogilvie is often cited by papers focused on Pharmacogenetics and Drug Metabolism (12 papers), Drug Transport and Resistance Mechanisms (10 papers) and Pharmacological Effects and Toxicity Studies (4 papers). Brian W. Ogilvie collaborates with scholars based in United States, Japan and Switzerland. Brian W. Ogilvie's co-authors include Andrew Parkinson, David B. Buckley, Paul Toren, Brandy L. Paris, Faraz Kazmi, Donglu Zhang, A. David Rodrigues, Wenying Li, Phyllis Yerino and Hiroyuki Kusuhara and has published in prestigious journals such as Journal of Pharmaceutical Sciences, Drug Metabolism and Disposition and Toxicology in Vitro.

In The Last Decade

Brian W. Ogilvie

24 papers receiving 876 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Brian W. Ogilvie United States 16 510 391 195 190 143 24 955
Kenneth J. Ruterbories United States 14 438 0.9× 290 0.7× 211 1.1× 133 0.7× 173 1.2× 37 990
David B. Buckley United States 17 499 1.0× 397 1.0× 420 2.2× 178 0.9× 122 0.9× 21 1.2k
Noriko Okudaira Japan 16 292 0.6× 346 0.9× 167 0.9× 205 1.1× 105 0.7× 25 753
Johanna Sistonen Finland 18 728 1.4× 345 0.9× 242 1.2× 300 1.6× 152 1.1× 34 1.3k
Takafumi Iwatsubo Japan 18 688 1.3× 524 1.3× 264 1.4× 140 0.7× 155 1.1× 33 1.2k
B K Park United Kingdom 14 423 0.8× 186 0.5× 299 1.5× 176 0.9× 133 0.9× 26 1.1k
Xavier Boulenc France 15 336 0.7× 303 0.8× 198 1.0× 94 0.5× 78 0.5× 19 814
Wataru Kishimoto Japan 15 431 0.8× 449 1.1× 224 1.1× 197 1.0× 69 0.5× 29 953
Leslie Z. Benet United States 16 308 0.6× 330 0.8× 146 0.7× 277 1.5× 131 0.9× 26 1.0k
Hidetaka Kamimura Japan 24 651 1.3× 676 1.7× 423 2.2× 255 1.3× 231 1.6× 98 1.6k

Countries citing papers authored by Brian W. Ogilvie

Since Specialization
Citations

This map shows the geographic impact of Brian W. Ogilvie's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian W. Ogilvie with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian W. Ogilvie more than expected).

Fields of papers citing papers by Brian W. Ogilvie

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian W. Ogilvie. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian W. Ogilvie. The network helps show where Brian W. Ogilvie may publish in the future.

Co-authorship network of co-authors of Brian W. Ogilvie

This figure shows the co-authorship network connecting the top 25 collaborators of Brian W. Ogilvie. A scholar is included among the top collaborators of Brian W. Ogilvie based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian W. Ogilvie. Brian W. Ogilvie is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Czerwiński, Maciej, et al.. (2022). In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions. Pharmacology Research & Perspectives. 10(3). e00959–e00959. 15 indexed citations
2.
Czerwiński, Maciej, et al.. (2022). In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions. Pharmacology Research & Perspectives. 10(3). e00958–e00958. 16 indexed citations
3.
Czerwiński, Maciej, et al.. (2019). Microsomal cytochrome P450 enzyme activities in nonalcoholic steatohepatitis livers. Drug Metabolism and Pharmacokinetics. 34(1). S25–S25. 1 indexed citations
4.
5.
Buckley, David B., Brian W. Ogilvie, & Phyllis Yerino. (2017). The in vitro evaluation of ketoconazole and its alternative clinical CYP3A4/5 inhibitors (ritonavir, clarithromycin and itraconazole) as inhibitors of non-CYP enzymes. Drug Metabolism and Pharmacokinetics. 32(1). S54–S54. 2 indexed citations
6.
Haupt, L., Faraz Kazmi, Brian W. Ogilvie, et al.. (2015). The Reliability of Estimating Ki Values for Direct, Reversible Inhibition of Cytochrome P450 Enzymes from Corresponding IC50 Values: A Retrospective Analysis of 343 Experiments. Drug Metabolism and Disposition. 43(11). 1744–1750. 50 indexed citations
7.
8.
Ogilvie, Brian W., Rosarelis Torres, Marlene Dressman, William G. Kramer, & Paolo Baroldi. (2015). Clinical assessment of drug–drug interactions of tasimelteon, a novel dual melatonin receptor agonist. The Journal of Clinical Pharmacology. 55(9). 1004–1011. 18 indexed citations
9.
Watanabe, Takao, Hiroyuki Kusuhara, Tomoko Watanabe, et al.. (2011). Prediction of the Overall Renal Tubular Secretion and Hepatic Clearance of Anionic Drugs and a Renal Drug-Drug Interaction Involving Organic Anion Transporter 3 in Humans by In Vitro Uptake Experiments. Drug Metabolism and Disposition. 39(6). 1031–1038. 75 indexed citations
10.
Parkinson, Andrew, Faraz Kazmi, David B. Buckley, et al.. (2011). An Evaluation of the Dilution Method for Identifying Metabolism-Dependent Inhibitors of Cytochrome P450 Enzymes. Drug Metabolism and Disposition. 39(8). 1370–1387. 58 indexed citations
11.
Eichenbaum, Gary, Andrew Parkinson, Mark D. Johnson, et al.. (2011). Use of Enzyme Inhibitors to Evaluate the Conversion Pathways of Ester and Amide Prodrugs: A Case Study Example with the Prodrug Ceftobiprole Medocaril. Journal of Pharmaceutical Sciences. 101(3). 1242–1252. 6 indexed citations
12.
Ogilvie, Brian W., Phyllis Yerino, Faraz Kazmi, et al.. (2011). The Proton Pump Inhibitor, Omeprazole, but Not Lansoprazole or Pantoprazole, Is a Metabolism-Dependent Inhibitor of CYP2C19: Implications for Coadministration with Clopidogrel. Drug Metabolism and Disposition. 39(11). 2020–2033. 79 indexed citations
13.
14.
15.
Nassar, Alaa-Eldin F., Ivan King, Brandy L. Paris, et al.. (2009). An in Vitro Evaluation of the Victim and Perpetrator Potential of the Anticancer Agent Laromustine (VNP40101M), Based on Reaction Phenotyping and Inhibition and Induction of Cytochrome P450 Enzymes. Drug Metabolism and Disposition. 37(9). 1922–1930. 14 indexed citations
16.
Paris, Brandy L., et al.. (2009). In Vitro Inhibition and Induction of Human Liver Cytochrome P450 Enzymes by Milnacipran. Drug Metabolism and Disposition. 37(10). 2045–2054. 53 indexed citations
17.
18.
Ogilvie, Brian W., Donglu Zhang, Wenying Li, et al.. (2005). GLUCURONIDATION CONVERTS GEMFIBROZIL TO A POTENT, METABOLISM-DEPENDENT INHIBITOR OF CYP2C8: IMPLICATIONS FOR DRUG-DRUG INTERACTIONS. Drug Metabolism and Disposition. 34(1). 191–197. 255 indexed citations
19.
Sweeny, David J., Juthamas Sukbuntherng, Qingling Zhang, et al.. (2005). Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416. Toxicology in Vitro. 20(2). 154–162. 31 indexed citations
20.
Antonian, Lida, Hongbing Zhang, Cheng Yang, et al.. (2000). Biotransformation of the Anti-Angiogenic Compound SU5416. Drug Metabolism and Disposition. 28(12). 1505–1512. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenneth J. Ruterbories Breakdown of academic impact, for papers by David B. Buckley Breakdown of academic impact, for papers by Noriko Okudaira Breakdown of academic impact, for papers by Johanna Sistonen Breakdown of academic impact, for papers by Takafumi Iwatsubo Breakdown of academic impact, for papers by B K Park Breakdown of academic impact, for papers by Xavier Boulenc Breakdown of academic impact, for papers by Wataru Kishimoto Breakdown of academic impact, for papers by Leslie Z. Benet Breakdown of academic impact, for papers by Hidetaka Kamimura
Rankless by CCL
2026